29

2023

-

11

Second-Half 2023 Insights into the Medical Device Industry: Changes in Clinical Needs and Behaviors


Since the end of July this year, the medical compliance campaign has been ongoing for more than three months, and industry standardization has already yielded significant results. During this period, monthly surgical volumes in different regions and departments have experienced noticeable short-term fluctuations. Looking ahead, normalized compliance marketing will remain a key focus of reform over the next five years. Coupled with the varying cycles of volume-based procurement across different product categories, the surgical volume market will continue to experience volatility under these dual influences, accelerating the divergence in demand for equipment and consumables. All these changes require companies to continuously monitor industry trends, rethink their product line management strategies, reevaluate market expansion approaches, and reshape their distribution channels.

The volume of surgeries fluctuates significantly.

01

2023 Surgical Volume: Affected by multiple policies—including compliance regulations, the pandemic, and centralized procurement—surgical volume has become increasingly volatile.

At the beginning of 2023, thanks to the optimized and adjusted epidemic prevention policies, surgical volumes experienced a sharp increase in the first quarter. However, starting in August, industry-standardization measures led to a decline in surgical volumes, with September and October seeing particularly significant drops. It is expected that after November, as corrective measures are gradually implemented, surgeons’ willingness to perform surgeries will begin to recover, reducing the impact on surgical volumes and gradually ushering in a growth trajectory. To some extent, industry standardization has slowed down the rebound in surgical volumes. Overall, for the full year 2023, surgical volumes are projected to grow by 9% compared to 2022; however, industry-standardization measures have somewhat curbed the overall annual growth rate by 3-4%.

In 2024, as major Grade-III hospitals expand and medical consortia are established, surgical procedures at leading Grade-III hospitals and regional central Grade-III hospitals are expected to rebound rapidly. Moreover, as DRG/CMI assessment systems continue to mature, high-quality surgical procedures will increasingly concentrate in core hospitals over the next three to five years. As a result, surrounding Grade-IIIB and Grade-IIB hospitals will be compelled to undergo transformation, honing their strengths in specific areas and pursuing differentiated development.

02

Departmental surgical volume: Industry compliance requirements have to some extent strengthened the implementation and standardization of volume-based procurement in public hospitals, thereby making departments more significantly affected by volume-based procurement.

Orthopedics, cardiology, and neurology all have products subject to large-scale volume-based procurement. As the use of non-tendered products becomes more restricted, the consumption of supplies and equipment used in surgery-related examinations and treatments is being tightened, leading to a certain decline in physicians’ enthusiasm for performing surgeries. Ophthalmic surgeries, which are predominantly conducted in private hospitals, have been relatively less affected; however, intraocular lens surgeries still face some restrictions. Departments where procurement is not centralized—such as cardiac surgery and breast and thyroid surgery—have also experienced only minor impacts on surgical volumes.

In 2024, robot-assisted surgical procedures (12.140, 0.13, 1.08%) are expected to grow at an even faster pace. In 2023, urology and orthopedics saw a sharp increase in the number of installed systems, which will lead to a substantial rise in endoscopic surgeries and robot-assisted joint replacements. Over the next three to five years, specialties with well-developed sub-specialties—such as orthopedics, urology, cardiology, and hepatobiliary surgery—are poised for unstoppable growth in surgical procedures, simultaneously driving a rapid increase in outpatient volumes.

03

Surgical Volume by Region/Segment: There is a certain correlation between the degree of regional impact and the progress of compliance. Regions that started implementation earlier have seen their decline in surgical volume narrow, while provinces that have been slower to implement are currently experiencing a drop in surgical volume.

*Market Definition

Core Market (1,507 hospitals): National, provincial, and major city medical centers

Expanding the market (1,900 hospitals): High-quality comprehensive hospitals in provincial and municipal areas; key hospitals in general prefecture-level cities.

Emerging markets (3,609 hospitals): District-level hospitals in cities of all levels and key hospitals in county-level cities.

Lower-tier markets (6,793 hospitals): District-level hospitals and employee hospitals in cities at all levels.

In some regions such as Tibet, Ningxia, Yunnan, and Gansu, the volume of surgeries in August declined significantly month-on-month. Meanwhile, provinces and cities that had previously seen strong surgical activity—such as Guangdong, Sichuan, and Chongqing—began to see a gradual recovery in September.

Each sub-market has been affected to varying degrees by the compliance process. In September, the impact gradually extended to emerging markets and lower-tier markets. Meanwhile, the core markets and expansion markets were initially hit more severely; currently, the decline in surgical volumes is starting to slow down.

The clinical use and demand behaviors for equipment and consumables are accelerating their divergence.

04

Equipment and consumable usage: In clinical settings, the use of equipment and consumables is beginning to show increasing differentiation. Physicians are particularly sensitive to auxiliary devices and consumables—especially those that are not disposable (particularly high-priced) equipment and consumables.

For stable and consolidated markets—particularly those featuring products that are not yet widely adopted but clinically highly necessary—physicians demonstrate a strong willingness to use these products, resulting in relatively minor impacts on overall usage frequency and volume. While companies seek to expand their market presence, they must also fully prepare for brand competition and differentiation.

For cautious, value-driven markets—particularly those featuring products that are already approved and clinically highly necessary—physicians’ willingness to adopt these products has slightly declined, and they tend to be somewhat more conservative in their choice of high-priced brands or high-priced subcategories. Companies need to ensure an adequate supply while also appropriately expanding the coverage of hospitals.

For competitive substitute markets (products that are not essential and have low necessity), the impact is significant. Physicians are highly sensitive, and there’s a growing trend toward substituting these products with similar, lower-priced conventional alternatives. Competition in this market will intensify further, so companies need to focus on retaining their core hospitals and core surgical procedures. In the short term, they can step up their efforts to establish a stronger presence in emerging markets.

For strategically retreating markets (products with low demand and low necessity), physicians’ decision-making largely depends on overall costs. Companies need to adopt different promotional strategies for high-priced versus low-priced procedures.

Reengineering enterprise management and urgently reforming product line management are now imperative.

05

In the medium to long term, the business environment will continue to be complex and ever-changing. In addition to product-line management, medical device companies will need to re-examine their strategies for expanding into new markets, building digital capabilities, and developing distribution channels. Only by constantly staying attuned to industry trends and adjusting strategic decisions can they break new ground and establish a new position in the market.

Layout of product portfolio derivatives: In fields such as surgery, orthopedics, and cardiovascular medicine, there are numerous successful cases where companies have effectively managed the lifecycle of their product portfolios to navigate complex macroeconomic environments. As product lifecycles accelerate, it becomes increasingly difficult for individual product lines to sustain themselves. In addition to the tiered management of existing products, companies also need to consider adopting strategies such as introducing new products from overseas, pursuing mergers and acquisitions, and engaging in independent R&D to develop a more comprehensive, long-term approach to managing the entire product lifecycle.

Careful planning is needed for new market deployments: While various sectors—including private hospitals, internet-based hospitals, and lower-tier markets—still present certain opportunities, the overall compliance process shows signs of expanding into internet-based hospitals and out-of-hospital markets. However, compliance measures do not necessarily lead to an overabundance of such markets. Enterprises need more urgently to rethink their policies, product adaptability, market capacity, and demand, and to comprehensively manage the expansion and expectations of target markets.

Omni-channel + digital transformation for information delivery: Digital promotion is not only compliant but also increasingly efficient as non-compliant sales models—such as cash-back sales—eventually fade away. Digital tools can gradually take over some of the simpler tasks involved in information dissemination. Enterprises need to think carefully about how to distinguish between the roles of sales representatives and digital information delivery, highlighting their respective strengths and synergies, and ensuring that digital channels form an efficient, closed-loop system.

Enhancing Sales and Channel Capabilities: Based on global compliance practices, all countries have established certain mechanisms to eliminate non-compliant behaviors such as sales involving kickbacks. Sales teams and channels should further strengthen their professional expertise and problem-solving capabilities. Moreover, companies should conduct a comprehensive review of their channel networks and proactively prepare for rapid transformation and adaptation.

Faced with a complex and ever-changing macro environment, IQVIA is committed to providing enterprises with customized database services and consulting expertise, empowering them to break through challenges in the new normal.